Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study
Clinical Rheumatology · 2026
DOI: 10.1007/s10067-026-08040-y ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Sébastien Ottaviani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service de Rhumatologie, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France. sebastien.ottaviani@aphp.fr. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Osteoporosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Inflammatory bowel diseases (IBDs) can be associated with bone fragility. We aimed to evaluate bone mineral density (BMD) in patients with IBD. METHODS: In this observational cross-sectional study, we consecutively included patients with IBD without previous diagnosis of low BMD. All patients underwent a standardized evaluation that included laboratory testing, dual-energy X-ray absorptiometry at the lumbar spine and hip to measure BMD and a systematic evaluation by a rheumatologist. RESULTS: We included 339 patients with IBD; 64% were women, and the median (interquartile range) age was 42 (32-53) years. BMD assessment revealed osteopenia in 115 (34%) patients and osteoporosis in 40 (12%). Multivariable analysis did not identify variables associated with low BMD. After the evaluation by the rheumatologist, vitamin D supplementation was initiated for 153 (45%) patients, and anti-osteoporosis treatment was started for 24 (7%). CONCLUSION: In this large cohort study, about 46% of patients with IBD had low BMD. Systematic evaluation led to the initiation of treatments in most patients. Altogether, our results promote multidisciplinary care of patients with IBD. Key points • Low bone mass density occurs in 42% of patients with inflammatory bowel diseases. • Age and female sex are associated with low bone mass density. After the evaluation by the rheumatologist, vitamin D supplementation and anti-osteoporosis treatment were initiated in a large number of patients. • A systematic multidisciplinary assessment for bone fragility could lead to better care of patients with inflammatory bowel disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Rhumatologie, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France. sebastien.ottaviani@aphp.fr.
- Institut Des MICI, Groupe Hospitalier Privé Ambroise Paré, Neuilly-Sur-Seine, France.
- Service de Rhumatologie, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
- Service de Gastroentérologie, MICI Et Assistance Nutritive, Hôpital Beaujon, APHP, Clichy, France.
- Service de Gastroentérologie, Hôpital Bichat, APHP, Paris, France.
Zitieren
APA
Ottaviani, S., Tréton, X., Forien, M., Stefanescu, C., Juge, P. A., Dermine, S., Pelletier, A. L., Becheur, H., Ebstein, E., Bouhnik, Y., & Dieudé, P. (2026). Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08040-y
Vancouver
Ottaviani S, Tréton X, Forien M, Stefanescu C, Juge PA, Dermine S, et al. Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08040-y
BibTeX
@article{Ottaviani2026,
author = {Ottaviani, Sébastien and Tréton, Xavier and Forien, Marine and Stefanescu, Carmen and Juge, Pierre-Antoine and Dermine, Solène and Pelletier, Anne-Laure and Becheur, Hakim and Ebstein, Esther and Bouhnik, Yoram and Dieudé, Philippe},
title = {Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study},
journal = {Clinical Rheumatology},
year = {2026},
doi = {10.1007/s10067-026-08040-y}
}
EUVIMED